Skip to Content
Merck
CN

SML0132

Sigma-Aldrich

Lanreotide acetate

≥98% (HPLC), SRIF-1 sst2 subtype of somatostatin receptor agonist, powder

Synonym(s):

3-(2-Naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide cyclic (2→7)-disulfide acetate, Angiopeptin acetate, BIM-23014C

Sign Into View Organizational & Contract Pricing

Select a Size

About This Item

Empirical Formula (Hill Notation):
C54H69N11O10S2 · xC2H4O2
CAS Number:
127984-74-1
Molecular Weight:
1096.32 (free base basis)
UNSPSC Code:
12352200
PubChem Substance ID:
329825182
NACRES:
NA.25

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Lanreotide acetate, ≥98% (HPLC)

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to off-white

shipped in

wet ice

storage temp.

−20°C

SMILES string

CC(O)=O.CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@H](N)Cc5ccc6ccccc6c5

InChI

1S/C54H69N11O10S2.C2H4O2/c1-29(2)45-54(75)63-44(53(74)65-46(30(3)66)47(57)68)28-77-76-27-43(62-48(69)38(56)23-32-15-18-33-10-4-5-11-34(33)22-32)52(73)60-41(24-31-16-19-36(67)20-17-31)50(71)61-42(25-35-26-58-39-13-7-6-12-37(35)39)51(72)59-40(49(70)64-45)14-8-9-21-55;1-2(3)4/h4-7,10-13,15-20,22,26,29-30,38,40-46,58,66-67H,8-9,14,21,23-25,27-28,55-56H2,1-3H3,(H2,57,68)(H,59,72)(H,60,73)(H,61,71)(H,62,69)(H,63,75)(H,64,70)(H,65,74);1H3,(H,3,4)/t30-,38-,40+,41+,42-,43+,44?,45+,46+;/m1./s1

InChI key

DEXPIBGCLCPUHE-HPDHVNDUSA-N

Related Categories

Application

Lanreotide acetate has been used as an inhibitor to test the plasticity of hydrogen sulfide modulation by growth hormone/thyroid hormone signaling in wild-type mice.

Biochem/physiol Actions

Lanreotide acetate is a somatostatin analog, a selective agonist for the SRIF-1 sst2 subtype of somatostatin receptor with a binding affinity of 0.8 nM for sst2 compared to 5.2 nM for sst5, 100 nM for sst3 and more than 1000 nM for the SRIF-2 subtypes, sst1 and sst4 receptors. It is used clinically in the management of acromegaly and symptoms caused by neuroendocrine tumors, and in recent studies can also inhibit tumor growth and has shown activity against non-endocrine tumors.
Octapeptide somatostatin analog; sst2 somatostatin receptor agonist; Antineoplastic

Pictograms

Health hazard
GHS08

Signal Word

Warning

Hazard Statements

H361

Precautionary Statements

P281

Hazard Classifications

Repr. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

涉药品监管产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000482799
0000482779
0000482799
0000482779
0000424559

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Christos Toumpanakis et al.
Seminars in oncology, 40(1), 56-68 (2013-02-09)
Somatostatin analogs (SA) are the standard of care for controlling symptoms of patients with functional gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs). SA control symptoms in more than 70% of patients with carcinoid syndrome. Similar results are obtained in patients with functional, hormone-secreting
Lucas Sidéris et al.
The oncologist, 17(6), 747-755 (2012-05-26)
For decades, somatostatin analogs (including octreotide and lanreotide) have been indicated for relief of the symptoms of flushing, diarrhea, and wheezing associated with secretory neuroendocrine tumors (NETs). Recently, it has been suggested that somatostatin analogs may provide direct and indirect
Ivan Borbath et al.
Acta gastro-enterologica Belgica, 75(2), 270-273 (2012-08-09)
We describe the case of a 54 years old woman, with hepatitis B, in whom the diagnosis of a 6 cm hepatocellular carcinoma (HCC) in the left liver was made in 2001. Alpha-foeto-protein (AFP) was 63 ng/mL (NI < 10
Maxime Palazzo et al.
European journal of gastroenterology & hepatology, 25(2), 232-238 (2012-10-31)
An antiproliferative effect of somatostatin analogs was recently demonstrated. To identify factors associated with tumor control in a group of patients with well-differentiated malignant digestive neuroendocrine tumors treated with lanreotide. A retrospective study was conducted in 68 patients treated with
Philippe J Caron et al.
The Journal of clinical endocrinology and metabolism, 99(4), 1282-1290 (2014-01-16)
Methodological shortcomings often compromise investigations into the effects of primary somatostatin-analog treatment on tumor size in acromegaly. There are also limited data for the long-acting lanreotide formulation. The aim of the study was to better characterize the effects of primary
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service